人大脑类器官模型及其在药物神经毒性研究中的应用

doi:10.3969/j.issn.1004-616x.2024.04.015

摘要/Abstract

摘要： 药物神经毒性是一种常见的药物不良反应，是药物研发和临床使用中重点关注的问题。为了全面了解药物对人体神经系统的潜在影响，需要建立能模拟人类神经系统的试验模型研究药物神经不良反应及其机制，从而减少药物不良反应发生，增加研发药物的安全性。由于人类大脑结构与功能的复杂性，当前常用的2D神经细胞模型、动物神经行为模型等存在一定局限性。人胚胎干细胞或人诱导多能干细胞衍生的人脑类器官，在结构功能与人脑更相似，保留了人脑遗传和分子表型。本文对人脑类器官模型在药物神经毒性方面的研究进展及应用进行综述，并探讨人脑类器官模型应用于药物研究和安全性评价时所面临的挑战。

关键词: 人脑类器官, 神经毒性, 安全性评价, 药物研究, 试验模型

中图分类号:

R745.1

刘哈晓雨, 卜迁, 田京伟, 岑小波. 人大脑类器官模型及其在药物神经毒性研究中的应用[J]. 癌变·畸变·突变, 2024, 36(4): 328-333.

参考文献

[1] PAŞCA A M, PARK J Y, SHIN H W, et al. Human 3D cellular model of hypoxic brain injury of prematurity[J]. Nat Med, 2019, 25(5): 784791.
[2] GENOVA E, CAVION F, LUCAFÒ M, et al. Induced pluripotent stem cells for therapy personalization in pediatric patients: focus on druginduced adverse events[J]. World J Stem Cells, 2019, 11(12): 1020-1044.
[3] DUTTA D, HEO I, CLEVERS H. Disease modeling in stem cellderived 3D organoid systems[J]. Trends Mol Med, 2017, 23(5): 393-410.
[4] UZQUIANO A, KEDAIGLE A J, PIGONI M, et al. Proper acquisition of cell class identity in organoids allows definition of fate specification programs of the human cerebral cortex[J]. Cell, 2022, 185(20): 3770- 3788.
[5] LANCASTER M A, RENNER M, MARTIN C A, et al. Cerebral organoids model human brain development and microcephaly[J]. Nature, 2013, 501(7467): 373-379.
[6] CAMP J G, BADSHA F, FLORIO M, et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development[J]. Proc Natl Acad Sci U S A, 2015, 112(51): 15672-15677.
[7] BU Q, DAI Y P, ZHANG H Q, et al. Neurodevelopmental defects in human cortical organoids with N-acetylneuraminic acid synthase mutation[J]. Sci Adv, 2023, 9(47): 2772.
[8] CHIARADIA I, LANCASTER M A. Brain organoids for the study of human neurobiology at the interface of in vitro and in vivo[J]. Nat Neurosci, 2020, 23(12): 1496-1508.
[9] QIAN X Y, NGUYEN H N, SONG M M, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure[J]. Cell, 2016, 165(5): 1238-1254.
[10] JO J, XIAO Y X, SUN A X, et al. Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelaninproducing neurons[J]. Cell Stem Cell, 2016, 19(2): 248-257.
[11] XIANG Y F, TANAKA Y, CAKIR B, et al. hESC-derived thalamic organoids form reciprocal projections when fused with cortical organoids [J]. Cell Stem Cell, 2019, 24(3): 487-497.
[12] HUANG W K, WONG S Z H, PATHER S R, et al. Generation of hypothalamic arcuate organoids from human induced pluripotent stem cells[J]. Cell Stem Cell, 2021, 28(9): 1657-1670.
[13] LEE J H, SHIN H, SHAKER M R, et al. Production of human spinal-cord organoids recapitulating neural-tube morphogenesis[J]. Nat Biomed Eng, 2022, 6(4): 435-448.
[14] HE Z S, MAYNARD A, JAIN A, et al. Lineage recording in human cerebral organoids[J]. Nat Methods, 2022, 19(1): 90-99.
[15] GIANDOMENICO S L, MIERAU S B, GIBBONS G M, et al. Cerebral organoids at the air-liquid interface generate diverse nerve tracts with functional output[J]. Nat Neurosci, 2019, 22(4): 669-679.
[16] BHADURI A, ANDREWS M G, MANCIA LEON W, et al. Cell stress in cortical organoids impairs molecular subtype specification[J]. Nature, 2020, 578(7793): 142-148.
[17] MANSOUR A A, GONÇALVES J T, BLOYD C W, et al. Erratum: an in vivo model of functional and vascularized human brain organoids[J]. Nat Biotechnol, 2018, 36(8): 772.
[18] LI M H, GAO L X, ZHAO L, et al. Toward the next generation of vascularized human neural organoids[J]. Med Res Rev, 2023, 43(1): 31-54.
[19] QIAN X Y, SU Y J, ADAM C D, et al. Sliced human cortical organoids for modeling distinct cortical layer formation[J]. Cell Stem Cell, 2020, 26(5): 766-781.
[20] ANDERSEN J, REVAH O, MIURA Y, et al. Generation of functional human 3D cortico-motor assembloids[J]. Cell, 2020, 183(7): 1913-1929.
[21] SCHAFER S T, MANSOUR A A, SCHLACHETZKI J C M, et al. An in vivo neuroimmune organoid model to study human microglia phenotypes [J]. Cell, 2023, 186(10): 2111-2126.e20.
[22] PARK D S, KOZAKI T, TIWARI S K, et al. iPS-cell-derived microglia promote brain organoid maturation via cholesterol transfer[J]. Nature, 2023, 623(7986): 397-405.
[23] HENDRIKS D, PAGLIARO A, ANDREATTA F, et al. Human fetal brain self-organizes into long-term expanding organoids[J]. Cell, 2024, 187(3): 712-732.
[24] MOORE T J, MOUSLIM M C, BLUNT J L, et al. Assessment of availability, clinical testing, and US food and drug administration review of biosimilar biologic products[J]. JAMA Intern Med, 2021, 181(1): 52-60.
[25] BAL-PRICE A, PISTOLLATO F, SACHANA M, et al. Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods[J]. Toxicol Appl Pharmacol, 2018, 354: 7-18.
[26] ELLIOTT R A, CAMACHO E, JANKOVIC D, et al. Economic analysis of the prevalence and clinical and economic burden of medication error in England[J]. BMJ Qual Saf, 2021, 30(2): 96-105.
[27] CROFTON K M, MUNDY W R, LEIN P J, et al. Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals[J]. ALTEX, 2011, 28(1): 9-15.
[28] JIANG M, TANG T X, LIANG X Y, et al. Maternal sevoflurane exposure induces temporary defects in interkinetic nuclear migration of radial glial progenitors in the fetal cerebral cortex through the Notch signalling pathway[J]. Cell Prolif, 2021, 54(6): e13042.
[29] ZHONG X L, HARRIS G, SMIRNOVA L, et al. Antidepressant paroxetine exerts developmental neurotoxicity in an iPSC-derived 3D human brain model[J]. Front Cell Neurosci, 2020, 14: 25.
[30] HUANG J, LIU F K, TANG H, et al. Tranylcypromine causes neurotoxicity and represses BHC110/LSD1 in human-induced pluripotent stem cell-derived cerebral organoids model[J]. Front Neurol, 2017, 8: 626.
[31] RAJAN S A P, ALEMAN J, WAN M M, et al. Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform[J]. Acta Biomater, 2020, 106: 124-135.
[32] SCHOLZ S, LEWIS K, SAULICH F, et al. Induced pluripotent stem cell-derived brain organoids as potential human model system for chemotherapy induced CNS toxicity[J]. Front Mol Biosci, 2022, 9: 1006497.
[33] LIU F K, HUANG J, LIU Z X. Vincristine impairs microtubules and causes neurotoxicity in cerebral organoids[J]. Neuroscience, 2019, 404: 530-540.
[34] HO M F, ZHANG C, MOON I, et al. Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder[J]. Mol Psychiatry, 2022. doi: 10.1038/s41380-022-01837-8.
[35] CRUCEANU C, DONY L, KRONTIRA A C, et al. Cell-type-specific impact of glucocorticoid receptor activation on the developing brain: a cerebral organoid study[J]. Am J Psychiatry, 2022, 179(5): 375-387.
[36] RABELING A, GOOLAM M. Cerebral organoids as an in vitro model to study autism spectrum disorders[J]. Gene Ther, 2023, 30(9): 659-669.
[37] FAIR S R, SCHWIND W, JULIAN D L, et al. Cerebral organoids containing an AUTS2 missense variant model microcephaly[J]. Brain, 2023, 146(1): 387-404.
[38] ZIVKO C, SAGAR R, XYDIA A, et al. iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer ' s disease[J]. Mol Psychiatry, 2024. doi: 10.1038/s41380-024-02629-y.
[39] SZEBÉNYI K, WENGER L M D, SUN Y, et al. Human ALS/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology[J]. Nat Neurosci, 2021, 24(11): 1542-1554.
[40] JARAZO J, BARMPA K, MODAMIO J, et al. Parkinson’s disease phenotypes in patient neuronal cultures and brain organoids improved by 2-hydroxypropyl-β-cyclodextrin treatment[J]. Mov Disord, 2022, 37(1): 80-94.
[41] KAGAN B J, KITCHEN A C, TRAN N T, et al. In vitro neurons learn and exhibit sentience when embodied in a simulated game-world[J]. Neuron, 2022, 110(23): 3952-3969.